Merck & Co.’s COVID-19 pill is giving rise to new mutations of the virus in some patients, according to a study that underscores the risk of trying to intentionally alter the pathogen’s genetic code.  Read moreStudy links Merck COVID-19 drug to new virus mutations

House Republicans have begun their promised aggressive oversight of the Biden administration. The focus Wednesday was on what watchdogs describe as “indications of widespread fraud” in federal coronavirus aid programs initiated under President Donald Trump. Read moreRepublican-led committee targets COVID relief aid for review

The Food and Drug Administration has withdrawn its provisional support for the use of Evusheld, a medication that was once a valuable tool for preventing patients with weakened immune systems from becoming severely ill with COVID-19. Read moreFDA revokes support for key anti-COVID-19 drug


"People will have to start paying some money for things they didn't have to pay for during the emergency," said Jen Kates, senior vice president at the Kaiser Family Foundation. Read moreThese benefits will disappear when Biden ends the COVID-19 emergencies in May


 President Joe Biden has informed Congress that he will end the twin national emergencies for addressing COVID-19 on May 11, as most of the world has returned closer to normalcy nearly three years after they were first declared.  Read morePresident Biden to end COVID-19 emergencies on May 11

The move to end the national and public health emergency declarations will formally restructure the federal coronavirus response to treat the virus as an endemic threat to public health that can be managed through agencies’ normal authorities. Read morePresident Biden to end COVID-19 emergencies on May 11


The World Health Organization chief says the coronavirus remains a global health emergency. It comes after a key advisory panel found the pandemic may be nearing an “inflexion point” where higher levels of immunity can lower deaths related to the virus. Director-General Tedros Adhanom Ghebreyesus told the annual meeting of its executive board meeting Monday that “there is no doubt that we’re in a far better situation now” than a year ago — when the highly transmissible Omicron variant was at its peak. Read moreWHO: COVID still an emergency but nearing 'inflection' point